Fundraising FoxFrazier Life Sciences — 2022 Investments
7 investments dated 2022 · listed companies and verified rows first · show all
MBX Biosciences is a clinical-stage biopharmaceutical company developing peptide therapeutics for endocrine and metabolic diseases.
BiotechHealthtechCarmel, US
Richard DiMarchi(Founder)Peter Kent Hawryluk(Executive Officer, Director)Timothy Knickerbocker(Executive Officer, Director)inSteve Hoerter(Chairman & Chief Executive Officer)inSalomon Azoulay(Chief Medical Officer)inKaren Basbaum(Chief Business Officer)in
Board seatPatrick Heron· per SEC Form D
Co-investorsNorwest Venture PartnersIU VenturesNew Enterprise Associates (NEA)OrbiMedWellington ManagementFrazier Healthcare Partners
BiotechWaltham, US
Chris Pacheco(Director)Carlos Loya(Executive Officer, Director)in
Board seatLauren Mifflin· per SEC Form D · $1.2M raise · filed Mar 2022
Sudo Biosciences develops small molecule therapeutics for neurological and immune-mediated inflammatory conditions.
BiotechHealthtechMedical DevicesMenlo Park, US
Jim Bristol(Director)Daniel Estes(Director)inScott Byrd(Executive Officer, Director)in
Board seatDaniel Estes· per SEC Form D
Co-investorsMonograph Capital PartnersPICUS CAPITALSanofi VenturesSV Health InvestorsDementia Discovery FundFrazier Healthcare Partners+2 more
Alpha-9 is a clinical-stage radiopharmaceutical company developing a portfolio of targeted molecules to treat cancer cells with precision.
BiotechLongevityMedical DevicesBoston, US
Co-investorsWUTIF CapitalAscenta CapitalBiotechnology Value FundLightspeed Venture PartnersLongitude CapitalNextech Invest+1 more
Aspen Neuroscience develops iPSC-derived autologous cell therapies for neurological diseases, with a lead product (ANPD001) in Phase 1/2a clinical trials for Parkinson's disease.
BiotechDeep TechDigital HealthMedical DevicesSan Diego, US
Andrés Bratt-Leal(Co-Founder and Senior Vice President, Research & Development)inANDRÉS BRATT-LEAL, Ph.D.(Co-Founder; Senior Vice President, Research & Development)Damien McDevitt(President and Chief Executive Officer)inDAMIEN MCDEVITT, Ph.D.(President and Chief Executive Officer)
Co-investorsARCH Venture PartnersLifeforce CapitalOrbiMedDomain AssociatesEDB InvestmentsSection 32+10 more
Metagenomi is a genetic medicines company developing therapies based on gene editing technologies to treat patients with serious diseases.
BiotechDeep TechHealthtechMedical DevicesBerkeley, US
Brian Thomas(Founder)inBrian Thomas Jillian Banfield(Founder)Jill Banfield(Founder)Jian Irish(President and CEO)
BoardAndrew Farquharson(Director)inJak Knowles(Director)
Co-investorsCatalio Capital Management, LPRA CapitalSozo VenturesAgent CapitalHumboldtInCube Ventures+5 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.